New York, New York–(Newsfile Corp. – April 6, 2026) – Levi & Korsinsky notifies investors that it has commenced an investigation into Immutep Limited (NASDAQ:IMMP) (“Immutep Limited”) concerning potential violations of the federal securities laws.
On January 30, 2026, Immutep filed a 6-K with the SEC stating that the TACTI-004 futility analysis was “on track for the first quarter of CY2026” and cited “strong operational progress” for the trial. The filing contained no reference to negative efficacy signals, enrollment difficulties, or data trends that might compromise the trial’s primary endpoints. Six weeks later, on March 13, 2026, the IDMC announced the interim futility analysis showed the drug was unlikely to succeed and recommended stopping the study. TACTI-004 was Immutep’s lead oncology asset.
The January 30 filing framed the futility analysis as a forward milestone still…
Treat every unsolicited “urgent” communication from a bank or government agency as a potential “Vishing” or “Smishing” attack, regardless of how official the branding or phone number appears.